{"nct_id":"NCT03350815","title":"Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis","status":"COMPLETED","status_verified_date":"2022-04","start_date":"2018-03-13","start_date_type":"ACTUAL","primary_completion_date":"2021-03-11","primary_completion_date_type":"ACTUAL","completion_date":"2021-05-29","completion_date_type":"ACTUAL","phases":["PHASE4"],"tickers":["NVS"]}